Dendritic cells (DCs) are the most potent antigen-presenting cells and are the key initiator of
tumor-specific immune responses. These characteristics are exploited by DC therapy, where …

Background Single-agent pembrolizumab represents the standard first-line option for
metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death …

Background In preclinical models, statins showed vaccine adjuvant activities and synergized
with PD-1 inhibitors. We analyzed the impact of statin treatment on clinical outcome in …

Background The role of immune-related adverse events (irAEs), as a surrogate predictor of
the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line …

Background Malignant pleural mesothelioma (MPM) is an aggressive, treatment resistant
neoplasm. The current treatment, consisting of antifolate and platinum-based chemotherapy …

Introduction Malignant mesothelioma (MM) is an aggressive cancer that primarily arises from
the pleura (MPM) or peritoneum (MPeM), mostly due to asbestos exposure. This study …

Background Randomized phase III trials are ongoing to investigate the efficacy of nivolumab
in malignant pleural mesothelioma (MPM), but real-world data are still scarce. In this real …

Background Malignant pleural mesothelioma (MPM) is a highly lethal malignancy in need
for new treatment options. Although immunotherapies have been shown to boost a tumor …

Immune checkpoint therapy (ICT) has the power to eradicate cancer, but the mechanisms
that determine effective therapy-induced immune responses are not fully understood. Here …

Malignant pleural mesothelioma (MPM) is a treatment recalcitrant tumor with a poor overall
survival (OS). Current approved treatment consists of first line chemotherapy that only …